ArticleVirchows Archiv : an international journal of pathology2009
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
Article in Virchows Archiv : an international journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.Disease markers · 2022Pooled it
- Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.Clinical epigenetics · 2016Pooled it
- Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Pooled it
- A Novel Prognostic DNA Methylation Panel for Colorectal Cancer.International journal of molecular sciences · 2019Trial
- Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- The oncogenic role of hypomethylated ZNF793 in gastric carcinoma: a focus on cell survival and stemness.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Value of the combination of intraepithelial tumor-infiltrating lymphocyte density and the heterogeneity of density as a prognostic marker in stage III colorectal cancers.Histology and histopathology · 2025Article
- Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer.Life (Basel, Switzerland) · 2025Review
- BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.International journal of molecular sciences · 2022Article
- CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?International journal of molecular sciences · 2022Review
- Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions.Gut and liver · 2021Review
- WNT5a in Colorectal Cancer: Research Progress and Challenges.Cancer management and research · 2021Review
- Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.BMC gastroenterology · 2019Article
- CpG Island Methylation in Sessile Serrated Adenoma/Polyp of the Colorectum: Implications for Differential Diagnosis of Molecularly High-Risk Lesions among Non-dysplastic Sessile Serrated Adenomas/Polyps.Journal of pathology and translational medicine · 2019Article
- Biomarkers in colorectal cancer: Current clinical utility and future perspectives.World journal of clinical cases · 2018Review
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.Seminars in cancer biology · 2018Review
- Colorectal cancer: epigenetic alterations and their clinical implications.Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers.Journal of gastrointestinal cancer · 2017Review
- CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.International journal of cancer · 2017Article
- Clinical and prognosis value of the CIMP status combined with MLH1 or p16Medical oncology (Northwood, London, England) · 2017Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CpG island methylator phenotype (CIMP) refers to a subset of colorectal cancers (CRCs) that are characterized by concordant hypermethylation of multiple CpG island loci. CIMP+ CRCs have peculiar clinicopathological features. However, controversy exists over prognostic implications of CIMP in CRCs. We analyzed 320 cases of CRCs for their CIMP status using the MethyLight assay and determined clinicopathological features and prognostic implications of CIMP alone or in combination with microsatellite instability (MSI). With methylation of five or more markers among eight markers examined, CIMP+ tumors were significantly associated with female gender, proximal tumor location, poor differentiation, nodal metastasis, more advanced cancer, BRAF mutations, MSI, and poor prognosis (all P values <0.05). Ogino's combined eight-marker panel outperformed the Ogino and the Laird five-marker panels in detecting these features. Of the four molecular subtypes generated by the combination of CIMP and MSI status, the CIMP+/MSI- subtype showed the worst clinical outcome (P = 0.0003). However, poor prognosis of CIMP+/MSI- subtype was found to be attributed to BRAF mutation. In conclusion, the CIMP+/MSI- subtype tends to present with distinct clinicopathological and molecular features and shows the worst clinical outcome among the four molecular subtypes of CRCs.
Indexed as
Identifiers
19911194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.